Floatz logo

FLUSPIRILENE

Schizophrenia and Disorders With Psychotic Features

Technical University of MunichSmall moleculePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

37 Active assets in the Schizophrenia and Disorders With Psychotic Features cohort.

Asset / SponsorPhaseRating
Risperdal
Northwell Health
Phase 4BBB
Olanzapine
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Asenapine
Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec
Phase 4BBB
Paliperidone Palmitate 3-Month Formulation
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Phase 4BBB
Haloperidol
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase 4BBB

View all 50 →

Same molecule, other indications

FLUSPIRILENE is also rated in:

schizoaffective disorderDormant
B
Indicative ·
62 / 100
View asset →
schizophreniaDormant
B
Indicative ·
57 / 100
View asset →
physiological malfunction arising from mental factorDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →